Skip to main
BDX

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 21%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson is well-positioned for growth and profitability with its diverse business units and success in navigating challenges. The company continues to invest in innovation and strategic acquisitions while also returning money to shareholders through share repurchases and debt reduction. Despite possible risks, BD's long-term outlook remains positive with strong Q1 results and a focus on driving growth and improving margins for increased shareholder returns.

Bears say

Becton Dickinson is a global medical technology company operating in the medical, life sciences, and interventional segments. While the recent launch of key products in the medical essentials and interventional segments show potential for growth, significant challenges in the connected care and biopharma systems divisions remain. Furthermore, the company's recent spin-off with Waters Corporation presents uncertainties about future financial performance. Despite potential upside scenarios, the negative outlook stems from concerns about revenue declines and uncertain impact of the spin-off on shareholder return.

BDX has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 14 analysts, BDX has a Buy consensus rating as of Jul 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $184.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $184.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.